Protocols for Creating Genetically-Transduced Animal Models of Ocular Hypertension and Glaucoma
- Authors: Najam A. Sharif1, Saima Chaudhry2
-
View Affiliations Hide Affiliations1 Research & Development Nanoscope Therapeutics Inc., 2777 N. Stemmons Fwy, Suite 1102, Dallas, TX 75207, USA 2 Univ N. Texas at Arlington, 701 S Nedderman Dr. Arlington, TX-76019, USA
- Source: Research Protocols for Ophthalmic Disease Mechanisms and Therapeutics: Glaucoma - Ocular Hypertension , pp 418-422
- Publication Date: August 2025
- Language: English
Protocols for Creating Genetically-Transduced Animal Models of Ocular Hypertension and Glaucoma, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9789815324334/chapter-38-1.gif
Several animal models of ocular hypertension (OHT) have been developed over the last two decades. Some researchers simply use naturally available naïve mammals such as rodents, rabbits, dogs, and monkeys to evaluate the effects of test agents. Other OHT researchers have created rodent models by ablating episcleral veins on the corneal surface using lasers or clips or filling them with hypertonic saline. In monkeys, the trabecular meshwork, the major aqueous humor (AQH) drainage system from the anterior chamber of the eye, can be partially coagulated using a laser to increase intraocular pressure (IOP). With the advent of genetical techniques, scientists have created gene knockout models of OHT. In the current chapter, the authors describe methods to genetically deliver genes into the anterior chamber and/or specific tissues that transduce the production of fibrotic cytokines such a transforming growth factor-beta (TGF-β2 ). This cytokine is abnormally elevated in AQH of OHT/glaucoma patients and is increasingly linked to the development of OHT/glaucoma.
-
From This Site
/content/books/9789815324334.chapter-38dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105